Concomitant use with a strong or moderate CYP3A inhibitor or a P-gp inhibitor increases venetoclax Cmax and AUC0-INF, which may increase venetoclax toxicities, including the risk of TLS.venetoclax
Concomitant use of venetoclax increases warfarin Cmax and AUC0-INF,which may increase the risk of bleeding. Monitor international normalized ratio (INR) more frequently in patients using warfarin concomitantly with venetoclax.
Concomitant use of venetoclax increases Cmax and AUC0-INF of P-gp substrates, which may increase toxicities of these substrates. Avoid concomitant use of venetoclax with a P-gp substrate. If a concomitant use is unavoidable, separate dosing of the P-gp substrate at least 6 hours before venetoclax.
from FDA,2022.06
Venetoclax reduces the viability of cancer cells by highly selectively inhibitin···【more】
Release date:2024-08-14Recommended:110
Venetoclax is a novel BCL-2 inhibitor that induces apoptosis in cancer cells by ···【more】
Release date:2024-08-14Recommended:129
Venetoclax is the world's only approved selective inhibitor of Bcl-2 that ca···【more】
Release date:2024-08-14Recommended:124